Loading...

Golden Meditech Holdings

OTCPK:GMDT.F
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GMDT.F
OTCPK
HK$2B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China. The last earnings update was 114 days ago. More info.


Add to Portfolio Compare Print
GMDT.F Share Price and Events
7 Day Returns
-6.4%
OTCPK:GMDT.F
3%
US Healthcare
1.2%
US Market
1 Year Returns
-9.3%
OTCPK:GMDT.F
8.2%
US Healthcare
3%
US Market
GMDT.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Golden Meditech Holdings (GMDT.F) -6.4% -6.4% 0.2% -9.3% -14.2% -48.5%
US Healthcare 3% -5.1% 3.1% 8.2% 28.3% 74%
US Market 1.2% 2.1% 14.6% 3% 39% 43.5%
1 Year Return vs Industry and Market
  • GMDT.F underperformed the Healthcare industry which returned 8.2% over the past year.
  • GMDT.F underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
GMDT.F
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Golden Meditech Holdings's competitors could be found in our database.

GMDT.F Value

 Is Golden Meditech Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Golden Meditech Holdings. This is due to cash flow or dividend data being unavailable. The share price is $0.103.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Golden Meditech Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Golden Meditech Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:GMDT.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in HKD HK$-0.20
SEHK:801 Share Price ** SEHK (2019-03-19) in HKD HK$0.79
United States of America Healthcare Industry PE Ratio Median Figure of 51 Publicly-Listed Healthcare Companies 21.25x
United States of America Market PE Ratio Median Figure of 3,058 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Golden Meditech Holdings.

OTCPK:GMDT.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:801 Share Price ÷ EPS (both in HKD)

= 0.79 ÷ -0.20

-4.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Golden Meditech Holdings is loss making, we can't compare its value to the US Healthcare industry average.
  • Golden Meditech Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Golden Meditech Holdings's expected growth come at a high price?
Raw Data
OTCPK:GMDT.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Healthcare Industry PEG Ratio Median Figure of 38 Publicly-Listed Healthcare Companies 1.63x
United States of America Market PEG Ratio Median Figure of 2,103 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Golden Meditech Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Golden Meditech Holdings's assets?
Raw Data
OTCPK:GMDT.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in HKD HK$1.64
SEHK:801 Share Price * SEHK (2019-03-19) in HKD HK$0.79
United States of America Healthcare Industry PB Ratio Median Figure of 91 Publicly-Listed Healthcare Companies 2.44x
United States of America Market PB Ratio Median Figure of 5,156 Publicly-Listed Companies 1.89x
OTCPK:GMDT.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:801 Share Price ÷ Book Value per Share (both in HKD)

= 0.79 ÷ 1.64

0.48x

* Primary Listing of Golden Meditech Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Golden Meditech Holdings is good value based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Golden Meditech Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Golden Meditech Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GMDT.F Future Performance

 How is Golden Meditech Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Golden Meditech Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Golden Meditech Holdings expected to grow at an attractive rate?
  • Unable to compare Golden Meditech Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Golden Meditech Holdings's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Golden Meditech Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:GMDT.F Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:GMDT.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:GMDT.F Future Estimates Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OTCPK:GMDT.F Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2018-09-30 298 -195 -575
2018-06-30 274 181 -641
2018-03-31 251 558 -708
2017-09-30 226 1,058 -407
2017-06-30 228 774 -422
2017-03-31 231 491 -437
2016-09-30 253 306 -584
2016-06-30 267 425 -495
2016-03-31 282 544 -406

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Golden Meditech Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Golden Meditech Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:GMDT.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Golden Meditech Holdings Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:GMDT.F Future Estimates Data
Date (Data in HKD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OTCPK:GMDT.F Past Financials Data
Date (Data in HKD Millions) EPS *
2018-09-30 -0.20
2018-06-30 -0.22
2018-03-31 -0.24
2017-09-30 -0.14
2017-06-30 -0.14
2017-03-31 -0.15
2016-09-30 -0.20
2016-06-30 -0.19
2016-03-31 -0.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Golden Meditech Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Golden Meditech Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Golden Meditech Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Golden Meditech Holdings's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Golden Meditech Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Golden Meditech Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GMDT.F Past Performance

  How has Golden Meditech Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Golden Meditech Holdings's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Golden Meditech Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Golden Meditech Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Golden Meditech Holdings's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Golden Meditech Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Golden Meditech Holdings Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:GMDT.F Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 297.56 -575.31 452.71
2018-06-30 274.14 -641.46 455.53
2018-03-31 250.72 -707.61 458.35
2017-09-30 226.06 -407.06 401.81
2017-06-30 228.36 -421.92 412.63
2017-03-31 230.67 -436.77 423.46
2016-09-30 252.70 -584.44 448.17
2016-06-30 267.13 -495.00 432.09
2016-03-31 281.56 -405.56 416.02
2015-09-30 -98.74 -1,113.93 204.13
2015-06-30 85.42 -988.84 252.61
2015-03-31 269.58 -863.75 301.10
2014-12-31 1,046.74 -499.23 637.62
2014-09-30 1,069.28 -303.08 646.26
2014-06-30 1,077.17 -366.08 627.53
2014-03-31 1,085.07 -429.08 608.81
2013-12-31 1,087.56 -196.39 564.21
2013-09-30 1,090.05 36.31 519.61
2013-06-30 1,084.55 85.99 517.62
2013-03-31 1,079.06 135.66 515.64
2012-12-31 1,143.85 148.57 534.43
2012-09-30 1,208.64 161.49 553.23
2012-06-30 1,052.26 157.18 474.30
2012-03-31 895.87 152.88 395.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Golden Meditech Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Golden Meditech Holdings has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Golden Meditech Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Golden Meditech Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Golden Meditech Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GMDT.F Health

 How is Golden Meditech Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Golden Meditech Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Golden Meditech Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Golden Meditech Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Golden Meditech Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Golden Meditech Holdings Company Filings, last reported 5 months ago.

OTCPK:GMDT.F Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 4,847.80 904.96 3,253.00
2018-06-30 4,847.80 904.96 3,253.00
2018-03-31 5,553.94 1,174.06 2,845.64
2017-09-30 4,077.36 3,019.73 231.36
2017-06-30 4,077.36 3,019.73 231.36
2017-03-31 4,030.83 3,003.83 495.34
2016-09-30 4,136.53 2,773.56 718.33
2016-06-30 4,136.53 2,773.56 718.33
2016-03-31 4,468.49 2,879.64 956.46
2015-09-30 4,288.33 3,008.45 4,290.54
2015-06-30 4,288.33 3,008.45 4,290.54
2015-03-31 4,636.25 2,791.45 4,191.88
2014-12-31 4,636.25 2,791.45 4,191.88
2014-09-30 5,467.40 1,827.04 3,234.03
2014-06-30 5,467.40 1,827.04 3,234.03
2014-03-31 5,850.48 1,618.70 2,884.29
2013-12-31 5,850.48 1,618.70 2,884.29
2013-09-30 6,130.67 1,682.73 2,502.36
2013-06-30 6,130.67 1,682.73 2,502.36
2013-03-31 6,126.34 1,479.34 2,376.83
2012-12-31 6,126.34 1,479.34 2,376.83
2012-09-30 5,227.64 227.33 574.82
2012-06-30 5,227.64 227.33 574.82
2012-03-31 5,860.12 709.21 1,913.79
  • Golden Meditech Holdings's level of debt (18.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (27.4% vs 18.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Golden Meditech Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
  • Golden Meditech Holdings has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 24.2% each year.
X
Financial health checks
We assess Golden Meditech Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Golden Meditech Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GMDT.F Dividends

 What is Golden Meditech Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Golden Meditech Holdings dividends.
If you bought $2,000 of Golden Meditech Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Golden Meditech Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Golden Meditech Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:GMDT.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2004 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:GMDT.F Future Dividends Estimate Data
Date (Data in HK$) Dividend per Share (annual) Avg. No. Analysts
OTCPK:GMDT.F Past Annualized Dividends Data
Date (Data in HK$) Dividend per share (annual) Avg. Yield (%)
2016-11-23 0.000 0.000
2016-06-28 0.000 0.000
2015-06-30 0.013 1.229
2014-07-24 0.026 2.068
2013-08-15 0.026 1.717
2012-06-27 0.020 1.109
2009-03-23 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Golden Meditech Holdings has not reported any payouts.
  • Unable to verify if Golden Meditech Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Golden Meditech Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Golden Meditech Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Golden Meditech Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Golden Meditech Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Golden Meditech Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GMDT.F Management

 What is the CEO of Golden Meditech Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yuen Kam
COMPENSATION HK$3,618,000
AGE 56
CEO Bio

Mr. Yuen Kam is the Founder of Golden Meditech Holdings Limited (also known as, Golden Meditech Company Limited) and serves as Chairman, Chief Executive Officer and Compliance Officer. Mr. Kam is responsible for Golden Meditech Company Limited's overall strategic planning. He has more than 20 years of management experience in Business and International Trade. He was the Chairman of China Cord Blood Corporation since October 03, 2012 until January 31, 2018. He has been Executive Director of Golden Meditech Holdings Limited since April 1, 2015. He serves as a Director of Bio Garden Inc. Mr. Kam serves as a Director at Magnum Opus 3 International Holdings Limited. Mr. Kam graduated from Beijing Second Foreign Languages Institute, the PRC in 1985.

CEO Compensation
  • Yuen's compensation has been consistent with company performance over the past year.
  • Yuen's remuneration is lower than average for companies of similar size in United States of America.
Management Team

Yuen Kam

TITLE
Founder
COMPENSATION
HK$4M
AGE
56

Wen Feng

TITLE
Executive Director
COMPENSATION
HK$1M
AGE
50

Kam Kong

TITLE
Company Secretary & Executive Director
COMPENSATION
HK$8M
AGE
49

Joanna Rui

TITLE
Investor Relations Manager

Zu Qin Lai

TITLE
Chief Scientist of Qijieyuan and Inventor of TangHerb
AGE
79

Jian Zhong Jing

TITLE
VP & Chief Representative of Shanghai Office
AGE
64

Dao Pei Lu

TITLE
President of Shanghai Dao Pei Hospital
AGE
86

Bao Ping Shao

TITLE
Chief Executive Officer of the Chinese Herbal Medicine Operation
AGE
52

Wei Zhong Ding

TITLE
Chief Executive Officer of GM Medicare Management (China) Company Limited
AGE
69

Fan Huang

TITLE
Chief Executive Officer of Medical Devices Operation
AGE
44
Board of Directors Tenure

Average tenure and age of the Golden Meditech Holdings board of directors in years:

6.5
Average Tenure
49.5
Average Age
  • The tenure for the Golden Meditech Holdings board of directors is about average.
Board of Directors

Wen Feng

TITLE
Executive Director
COMPENSATION
HK$1M
AGE
50
TENURE
6.5 yrs

Kam Kong

TITLE
Company Secretary & Executive Director
COMPENSATION
HK$8M
AGE
49
TENURE
6.5 yrs

Albert Chen

TITLE
CFO & Executive Director of China Cord Blood Corporation
AGE
42

Ming Li Zhang

TITLE
Chairman of Technology Development Advisory Board

Yuen Kam

TITLE
Founder
COMPENSATION
HK$4M
AGE
56

Gang Cao

TITLE
Independent Non-Executive Director
COMPENSATION
HK$1M
AGE
73
TENURE
3.5 yrs

Yue Gao

TITLE
Independent Non Executive Director
COMPENSATION
HK$1M
AGE
45
TENURE
4.3 yrs

Qiao Gu

TITLE
Independent Non-Executive Director
COMPENSATION
HK$1M
AGE
71
TENURE
17.5 yrs

Tina Zheng

TITLE
Non-Executive Director
AGE
46
TENURE
6.6 yrs

Xue Tao Pei

TITLE
Member of Technology Development Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Aug 18 Buy Yang Liu Individual 13. Aug 18 13. Aug 18 30,000,000 $0.11 $3,376,890
15. Aug 18 Buy Atlantis Investment Management (Ireland) Limited Company 13. Aug 18 13. Aug 18 30,000,000 $0.11 $3,376,890
19. Jul 18 Buy Yang Liu Individual 15. Jul 18 15. Jul 18 884,000 $0.11 $100,644
28. Jun 18 Buy Yang Liu Individual 25. Jun 18 25. Jun 18 2,252,000 $0.11 $257,994
25. Apr 18 Buy Yuen Kam Individual 24. Apr 18 24. Apr 18 500,000 $0.11 $54,798
24. Apr 18 Buy Yuen Kam Individual 23. Apr 18 23. Apr 18 20,000 $0.11 $2,218
24. Apr 18 Buy Yuen Kam Individual 20. Apr 18 20. Apr 18 2,364,000 $0.11 $263,090
20. Apr 18 Buy Yuen Kam Individual 19. Apr 18 19. Apr 18 500,000 $0.11 $54,156
09. Apr 18 Buy Yuen Kam Individual 28. Mar 18 28. Mar 18 1,000,000 $0.11 $111,501
28. Mar 18 Buy Yuen Kam Individual 27. Mar 18 27. Mar 18 4,000 $0.11 $449
27. Mar 18 Buy Yuen Kam Individual 26. Mar 18 26. Mar 18 688,000 $0.11 $76,289
26. Mar 18 Buy Yuen Kam Individual 23. Mar 18 23. Mar 18 8,000 $0.11 $887
22. Mar 18 Buy Yuen Kam Individual 22. Mar 18 22. Mar 18 608,000 $0.11 $68,957
X
Management checks
We assess Golden Meditech Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Golden Meditech Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GMDT.F News

Simply Wall St News

GMDT.F Company Info

Description

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China. It operates through five segments: Medical Devices, Hospital Business, Medical Insurance Administration, Chinese Herbal Medicines, and Cells and Tissues Storage and Genetic Testing Services. The Medical Devices segment develops, manufactures, and sells medical devices and accessories. This segment provides products that are specialized in blood recovery, purification, and treatment. The Hospital Business segment offers hospital management services; and operates hospitals in Beijing and Shanghai that provide obstetrics, gynecology, and pediatric medical services, as well as haematology treatments and healthcare services. The Medical Insurance Administration segment offers medical insurance administration services. This segment also provides operational and information technology solutions to medical insurance companies and healthcare institutions, as well as offers claims, review process, bill settlement, and data analysis services. The Chinese Herbal Medicine segment is involved in the research, development, manufacture, and sale of Chinese herbal medicines. The Cells and Tissues Storage and Genetic Testing Services segment engages in the provision of cells and tissues storage services, as well as related clinical applications. This segment also provides genetic testing and molecular pathology testing services. The company also engages in the software design business. The company was formerly known as Golden Meditech Company Limited and changed its name to Golden Meditech Holdings Limited in March 2010. Golden Meditech Holdings Limited was incorporated in 2001 and is headquartered in Beijing, the People’s Republic of China.

Details
Name: Golden Meditech Holdings Limited
GMDT.F
Exchange: OTCPK
Founded: 2001
HK$293,552,254
2,916,932,138
Website: http://www.goldenmeditech.com
Address: Golden Meditech Holdings Limited
No. 11 Wan Yuan Street,
Beijing Economic Technological Development Area,
Beijing,
100176,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 801 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 28. Dec 2001
OTCPK GMDT.F Ordinary Shares Pink Sheets LLC US USD 28. Dec 2001
Number of employees
Current staff
Staff numbers
956
Golden Meditech Holdings employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 23:58
End of day share price update: 2019/03/19 00:00
Last estimates confirmation: 2017/06/28
Last earnings filing: 2018/11/26
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.